Avadel Pharmaceuticals (AVDL) Return on Equity: 2009-2021
Historic Return on Equity for Avadel Pharmaceuticals (AVDL) over the last 11 years, with Dec 2021 value amounting to -1.00%.
- Avadel Pharmaceuticals' Return on Equity fell 112.00% to -1.00% in Q4 2021 from the same period last year, while for Dec 2021 it was -1.00%, marking a year-over-year decrease of 112.00%. This contributed to the annual value of -0.71% for FY2021, which is 62.00% down from last year.
- Avadel Pharmaceuticals' Return on Equity amounted to -1.00% in Q4 2021, which was down 60.89% from -0.62% recorded in Q3 2021.
- Avadel Pharmaceuticals' 5-year Return on Equity high stood at 28.25% for Q1 2019, and its period low was -51.18% during Q1 2020.
- Its 3-year average for Return on Equity is -0.89%, with a median of -0.01% in 2020.
- As far as peak fluctuations go, Avadel Pharmaceuticals' Return on Equity plummeted by 7,943bps in 2020, and later soared by 5,128bps in 2021.
- Avadel Pharmaceuticals' Return on Equity (Quarterly) stood at 2.20% in 2017, then slumped by 498bps to -2.78% in 2018, then skyrocketed by 549bps to 2.71% in 2019, then crashed by 258bps to 0.13% in 2020, then tumbled by 112bps to -1.00% in 2021.
- Its last three reported values are -1.00% in Q4 2021, -0.62% for Q3 2021, and -0.42% during Q2 2021.